spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

The Latest Innovations in HPAPI Manufacturing Technologies

SMI Adaptive Designs in Clinical Trials 2019


Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other points to be discussed include:

- Alternative drug manufacture through nanocrystal formulations, thin films and hot-melt extrusion/injection molding that reduces HPAPI powder exposure and improve safety
- Step-by-step processes along with the equipment needed to achieve alternative HPAPI manufacturing techniques

Richard Denk, Head of Sales Containment from SKAN focuses on:
- Regulatory requirements for highly potent biologics-based Pharmaceuticals
- Requirements for aseptic manufacturing and Containment
- Cleaning and Cross Contamination Requirements

Also, up for discussion will be emerging bispecific HPAPI therapy, from development to manufacturing and multipurpose facilities, along with what level of super high-level band 5 containment is required.

For those interested, a special discounted rate is available for conference tickets booked before August 30th. Register online at www.hpapi-usa.com/PR4

Sponsored by BSP Pharmaceuticals | LONZA | Minakem | SafeBridge Consultants

Highly Potent Active Pharmaceutical Ingredients USA

Conference: October 21st – 22nd
Workshops: October 23rd
Venue: Sheraton Boston Hotel, USA

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184 or fbegum@smi-online.co.uk

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 or nhoward@smi-online.co.uk

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
phone +44 (0)20 7827 6000
email events@smi-online.co.uk
web bit.ly/2DNvPs7
email London
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>


White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement